Literature DB >> 23365673

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Laura Christensen1, Jay Joo, Sean Lee, Daniel Wai, Timothy J Triche, William A May.   

Abstract

Ewing Family Tumors (Ewing Sarcoma and peripheral Primitive Neuroectodermal Tumor) are common bone and soft tissue malignancies of childhood, adolescence and young adulthood. Chromosomal translocation in these tumors produces fusion oncogenes of the EWS/ETS class, with EWS/FLI1 being by far the most common. EWS/ETS chimera are the only well established driver mutations in these tumors and they function as aberrant transcription factors. Understanding the downstream genes whose expression is modified has been a central approach to the study of these tumors. FOXM1 is a proliferation associated transcription factor which has increasingly been found to play a role in the pathogenesis of a wide range of human cancers. Here we demonstrate that FOXM1 is expressed in Ewing primary tumors and cell lines. Reduction in FOXM1 expression in Ewing cell lines results in diminished potential for anchorage independent growth. FOXM1 expression is enhanced by EWS/FLI1, though, unlike other tumor systems, it is not driven by expression of the EWS/FLI1 target GLI1. Thiostrepton is a compound known to inhibit FOXM1 by direct binding. We show that Thiostrepton diminishes FOXM1 expression in Ewing cell lines and this reduction reduces cell viability through an apoptotic mechanism. FOXM1 is involved in Ewing tumor pathogenesis and may prove to be a useful therapeutic target in Ewing tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365673      PMCID: PMC3554707          DOI: 10.1371/journal.pone.0054556

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  40 in total

1.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

2.  Thiostrepton, proteasome inhibitors and FOXM1.

Authors:  Andrei L Gartel
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 3.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

4.  FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis.

Authors:  Nu Zhang; Ping Wei; Aihua Gong; Wen-Tai Chiu; Hsueh-Te Lee; Howard Colman; He Huang; Jianfei Xue; Mingguang Liu; Yong Wang; Raymond Sawaya; Keping Xie; W K Alfred Yung; René H Medema; Xi He; Suyun Huang
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

5.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.

Authors:  W A May; M L Gishizky; S L Lessnick; L B Lunsford; B C Lewis; O Delattre; J Zucman; G Thomas; C T Denny
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

6.  Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.

Authors:  Markus Priller; Julia Pöschl; Leticia Abrão; André O von Bueren; Yoon-Jae Cho; Stefan Rutkowski; Hans A Kretzschmar; Ulrich Schüller
Journal:  Clin Cancer Res       Date:  2011-09-14       Impact factor: 12.531

7.  FoxM1: a master regulator of tumor metastasis.

Authors:  Pradip Raychaudhuri; Hyun Jung Park
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

8.  Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.

Authors:  James S Miser; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; Holcolmbe E Grier
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

9.  FOXM1 is a downstream target of Gli1 in basal cell carcinomas.

Authors:  Muy-Teck Teh; Soon-Tee Wong; Graham W Neill; Lucy R Ghali; Michael P Philpott; Anthony G Quinn
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.

Authors:  Gabriel T M Lok; David W Chan; Vincent W S Liu; Winnie W Y Hui; Thomas H Y Leung; K M Yao; Hextan Y S Ngan
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

View more
  18 in total

1.  FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.

Authors:  Masaaki Kuda; Kenichi Kohashi; Yuichi Yamada; Akira Maekawa; Yoshiaki Kinoshita; Tetsuya Nakatsura; Yukihide Iwamoto; Tomoaki Taguchi; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-11-09

2.  The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.

Authors:  Aniruddha Sengupta; Mahbubur Rahman; Silvia Mateo-Lozano; Oscar M Tirado; Vicente Notario
Journal:  Int J Oncol       Date:  2013-07-12       Impact factor: 5.650

3.  FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.

Authors:  Zuhal Hamurcu; Ahmed Ashour; Nermin Kahraman; Bulent Ozpolat
Journal:  Oncotarget       Date:  2016-03-29

4.  Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.

Authors:  Akira Maekawa; Kenichi Kohashi; Masaaki Kuda; Kunio Iura; Takeaki Ishii; Makoto Endo; Tetsuya Nakatsura; Yukihide Iwamoto; Yoshinao Oda
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

Review 5.  EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.

Authors:  Florencia Cidre-Aranaz; Javier Alonso
Journal:  Front Oncol       Date:  2015-07-20       Impact factor: 6.244

6.  MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.

Authors:  MinRan Zhou; JiPing Zeng; XiaoMing Wang; Qing Guo; Tao Huang; HaiYu Shen; Yue Fu; LiXiang Wang; JiHui Jia; ChunYan Chen
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531

7.  Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.

Authors:  Akira Maekawa; Kenichi Kohashi; Nokitaka Setsu; Masaaki Kuda; Kunio Iura; Takeaki Ishii; Tomoya Matsunobu; Tetsuya Nakatsura; Yukihide Iwamoto; Yoshinao Oda
Journal:  Cancer Sci       Date:  2016-01-12       Impact factor: 6.716

8.  Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.

Authors:  Camille Jacques; François Lamoureux; Marc Baud'huin; Lidia Rodriguez Calleja; Thibaut Quillard; Jérôme Amiaud; Franck Tirode; Françoise Rédini; James E Bradner; Dominique Heymann; Benjamin Ory
Journal:  Oncotarget       Date:  2016-04-26

9.  Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer.

Authors:  Jing Zhang; Kundong Zhang; Lisheng Zhou; Weidong Wu; Tao Jiang; Jun Cao; Kejian Huang; Zhengjun Qiu; Chen Huang
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

Review 10.  FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways.

Authors:  Fergal C Kelleher; Hazel O'Sullivan
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.